PMID- 35740494
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Jun 8
TI  - Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine 
      Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor 
      Prognosis.
LID - 10.3390/cancers14122828 [doi]
LID - 2828
AB  - Tumor grading is a robust prognostic predictor in patients with neuroendocrine 
      neoplasms (NEN) and guides therapy, especially in tumors with high proliferation. 
      NEN can be separated into well-differentiated and poorly differentiated types. 
      The more aggressive NEN have been further separated into neuroendocrine tumors 
      (NET G3) with a better prognosis and neuroendocrine carcinomas (NEC) with a worse 
      prognosis. Despite this distinction's tremendous clinical and therapeutic 
      relevance, optimal diagnostic biomarkers are still lacking. In this study, we 
      analyzed the protein expression and prognostic impact of Enhancer of Zeste 
      Homolog 2 (EZH2) by immunohistochemistry in 219 tissue samples of 
      gastroenteropancreatic (GEP-NEN) and pulmonary NEN (P-NEN). EZH2 was almost 
      exclusively expressed in NEN with a proliferation rate above 20% (G3), while all 
      low-grade tumors were nearly negative. Among high-grade NEN, 65% showed high and 
      35% low expression of EZH2. In this group, the high expression of EZH2 was 
      significantly associated with poor overall survival and NEC histology. 
      Interestingly, EZH2 seems to act independently of Polycomb Repressive Complex 2 
      (PRC2) in NEN. In conclusion, we propose EZH2 as a robust biomarker for 
      distinguishing between NET G3 and NEC among gastroenteropancreatic and pulmonary 
      NEN.
FAU - Bremer, Sebastian C B
AU  - Bremer SCB
AUID- ORCID: 0000-0001-5481-0429
AD  - Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, 
      University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, 
      Germany.
FAU - Bittner, Gabi
AU  - Bittner G
AD  - Institute of Pathology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Elakad, Omar
AU  - Elakad O
AD  - Institute of Pathology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Dinter, Helen
AU  - Dinter H
AD  - Institute of Pathology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Gaedcke, Jochen
AU  - Gaedcke J
AUID- ORCID: 0000-0002-6130-5874
AD  - Clinic for General, Visceral and Pediatric Surgery, University Medical Center 
      Goettingen, Georg-August-University, 37075 Goettingen, Germany.
FAU - Konig, Alexander O
AU  - Konig AO
AD  - Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, 
      University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, 
      Germany.
FAU - Amanzada, Ahmad
AU  - Amanzada A
AUID- ORCID: 0000-0002-0801-2087
AD  - Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, 
      University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, 
      Germany.
FAU - Ellenrieder, Volker
AU  - Ellenrieder V
AD  - Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, 
      University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, 
      Germany.
FAU - Freiherr von Hammerstein-Equord, Alexander
AU  - Freiherr von Hammerstein-Equord A
AD  - Clinic for Cardiac, Thoracic and Vascular Surgery, University Medical Center 
      Goettingen, Georg-August-University, 37075 Goettingen, Germany.
FAU - Strobel, Philipp
AU  - Strobel P
AD  - Institute of Pathology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Bohnenberger, Hanibal
AU  - Bohnenberger H
AUID- ORCID: 0000-0003-1038-1030
AD  - Institute of Pathology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
LA  - eng
GR  - 70112551/German Cancer Aid/
GR  - Else Kroner-Forschungskolleg fur "Molekulare Therapie und Pradiktion bei 
      gastrointestinalen Malignomen"/Else Kroner-Fresenius-Stiftung/
PT  - Journal Article
DEP - 20220608
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9221317
OTO - NOTNLM
OT  - EZH2
OT  - neuroendocrine neoplasia
OT  - survival
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/06/08
CRDT- 2022/06/24 01:06
PHST- 2022/03/10 00:00 [received]
PHST- 2022/05/29 00:00 [revised]
PHST- 2022/06/04 00:00 [accepted]
PHST- 2022/06/24 01:06 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/06/08 00:00 [pmc-release]
AID - cancers14122828 [pii]
AID - cancers-14-02828 [pii]
AID - 10.3390/cancers14122828 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Jun 8;14(12):2828. doi: 10.3390/cancers14122828.